Cargando…

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis

Venetoclax (VEN) combined with azacitidine (AZA) or decitabine (DEC) has been approved for older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy based on the pivotal VIALE-A trial. However, this trial only compared AZA + VEN with AZA monotherapy. Therefore, we compared the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwag, Daehun, Cho, Byung-Sik, Bang, Su-Yeon, Lee, Jong Hyuk, Min, Gi-June, Park, Sung-Soo, Park, Silvia, Yoon, Jae-Ho, Lee, Sung-Eun, Eom, Ki-Seong, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Lee, Jong Wook, Kim, Hee-Je
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760636/ https://www.ncbi.nlm.nih.gov/pubmed/36529771 http://dx.doi.org/10.1038/s41408-022-00770-x

Ejemplares similares

A Successful Bridge Therapy Combining Hypomethylating Agents with Venetoclax for Adult Patients with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy
por: Shin, Seung-Hwan, et al.
Publicado: (2017)

Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–matched cohort analysis
por: Yoon, Jae-Ho, et al.
Publicado: (2023)

A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)
por: Park, Silvia, et al.
Publicado: (2022)

Dynamic changes in physical function during intensive chemotherapy affect transplant outcomes in older adults with AML
por: Min, Gi-June, et al.
Publicado: (2023)

Haploidentical versus Double-Cord Blood Stem Cells as a Second Transplantation for Relapsed Acute Myeloid Leukemia
por: Lee, Jong-Hyuk, et al.
Publicado: (2023)

Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome
por: Han, Seunghoon, et al.
Publicado: (2015)

Hepatic venoocclusive disease/sinusoidal obstruction syndrome with normal portal vein flow mimicking aggravated chronic hepatic GVHD following inotuzumab ozogamicin salvage therapy: a case report of pathologic-radiologic discrepancy
por: Lee, Joonyeop, et al.
Publicado: (2021)

Mixed-phenotype acute leukemia treated with decitabine
por: Lee, Ji-Young, et al.
Publicado: (2016)

T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
por: Park, Sungwoo, et al.
Publicado: (2023)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients
por: Kim, Tong-Yoon, et al.
Publicado: (2022)

Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia
por: Park, Hyunsung, et al.
Publicado: (2017)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
por: Kwon, Yong-Rim, et al.
Publicado: (2020)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

HLA-mismatched donor and high ferritin level showed poor clinical outcomes after allogeneic hematopoietic cell transplantation in patients with advanced myelofibrosis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features for early and long-term mortality
por: Yoon, Jae-Ho, et al.
Publicado: (2022)

Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults
por: Yoo, Kwai Han, et al.
Publicado: (2020)

Long-term treatment outcome of Castleman’s disease: A real-world experience
por: Min, Gi-June, et al.
Publicado: (2022)

The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia
por: Santini, Valeria, et al.
Publicado: (2021)

Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome‐negative acute lymphoblastic leukemia in first salvage
por: Yoon, Jae‐Ho, et al.
Publicado: (2019)

Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2019)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
por: Klocke, Heather, et al.
Publicado: (2020)

FRI645 A Case Of Diabetic Ketoacidosis After Initiation Of Decitabine And Venetoclax Chemotherapy
por: Maini, Rohan, et al.
Publicado: (2023)

P524: PHARMACODYNAMICALLY DEFINED METRONOMIC DOSING OF DECITABINE AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Fedorov, Kateryna, et al.
Publicado: (2023)

Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin’s lymphoma
por: Jeon, Young-Woo, et al.
Publicado: (2019)

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
por: Jeon, Young‐Woo, et al.
Publicado: (2019)

Di-O-lauroyl-decitabine-lipid nanocapsules: toward extending decitabine activity
por: Briot, Thomas, et al.
Publicado: (2019)

A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome
por: Jeong, Seong Hyun, et al.
Publicado: (2015)

Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab
por: Shoumariyeh, Khalid, et al.
Publicado: (2021)

Comparison of the effects of early intensified induction chemotherapy and standard 3+7 chemotherapy in adult patients with acute myeloid leukemia
por: Yoon, Jae-Ho, et al.
Publicado: (2017)

Distinct Clinical Outcomes between Paramedullary and Extramedullary Lesions in Newly Diagnosed Multiple Myeloma
por: Batsukh, Khishigjargal, et al.
Publicado: (2017)

The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine
por: Kim, Mihee, et al.
Publicado: (2023)

Treatment for relapsed acute promyelocytic leukemia: what is the best post-remission treatment?
por: Min, Gi-June, et al.
Publicado: (2022)

Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective phase II observational study
por: Oh, Eun-Jee, et al.
Publicado: (2021)

Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
por: Rahmat, Leena T., et al.
Publicado: (2018)

Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T‐cell lymphoblastic leukemia
por: Zappone, Elisabetta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1ghr74s848epuni6vpgaj456uh